Phospholipid metabolites in recurrent glioblastoma: in vivo markers detect different tumor phenotypes before and under antiangiogenic therapy.
<h4>Purpose</h4>Metabolic changes upon antiangiogenic therapy of recurrent glioblastomas (rGBMs) may provide new biomarkers for treatment efficacy. Since in vitro models showed that phospholipid membrane metabolism provides specific information on tumor growth we employed in-vivo MR-spec...
Saved in:
Main Authors: | Elke Hattingen, Oliver Bähr, Johannes Rieger, Stella Blasel, Joachim Steinbach, Ulrich Pilatus |
---|---|
Format: | article |
Language: | EN |
Published: |
Public Library of Science (PLoS)
2013
|
Subjects: | |
Online Access: | https://doaj.org/article/7600f252df9b49f49e3e4c0871c525d7 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antiangiogenic therapy for breast cancer with triple negative phenotype
by: Inna P. Ganshina, et al.
Published: (2021) -
Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far
by: Clavreul A, et al.
Published: (2019) -
Vascular Hysteresis Loops and Vascular Architecture Mapping in Patients with Glioblastoma treated with Antiangiogenic Therapy
by: Andreas Stadlbauer, et al.
Published: (2017) -
ROLE OF PRO- AND ANTIANGIOGENIC FACTORS IN PLACENTAL DEVELOPMENT
by: D. I. Sokolov, et al.
Published: (2014) -
Antiangiogenic properties of nanoparticles: a systematic review
by: Saeed BA, et al.
Published: (2019)